Evidence map›Paper›PMID 36276136›Full record

ArticleFrontiers in oncology2022

Predicting IDH subtype of grade 4 astrocytoma and glioblastoma from tumor radiomic patterns extracted from multiparametric magnetic resonance images using a machine learning approach.

Pashmina Kandalgaonkar, Arpita Sahu, Ann Christy Saju, Akanksha Joshi, Abhishek Mahajan, Meenakshi Thakur, Ayushi Sahay, Sridhar Epari, Shwetabh Sinha, Archya Dasgupta and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Pashmina KandalgaonkarDepartment of Radiodiagnosis, Tata Memorial Center, Mumbai, India.
Arpita SahuDepartment of Radiodiagnosis, Tata Memorial Center, Mumbai, India.
Ann Christy SajuHomi Bhabha National Institute, Mumbai, India.
Akanksha JoshiDepartment of Radiodiagnosis, Tata Memorial Center, Mumbai, India.
Abhishek MahajanDepartment of Radiodiagnosis, Tata Memorial Center, Mumbai, India.
Meenakshi ThakurDepartment of Radiodiagnosis, Tata Memorial Center, Mumbai, India.
Ayushi SahayHomi Bhabha National Institute, Mumbai, India.
Sridhar EpariHomi Bhabha National Institute, Mumbai, India.
Shwetabh SinhaHomi Bhabha National Institute, Mumbai, India.
Archya DasguptaHomi Bhabha National Institute, Mumbai, India.
Abhishek ChatterjeeHomi Bhabha National Institute, Mumbai, India.
Prakash ShettyHomi Bhabha National Institute, Mumbai, India.
Aliasgar MoiyadiHomi Bhabha National Institute, Mumbai, India.
Jaiprakash AgarwalHomi Bhabha National Institute, Mumbai, India.
Tejpal GuptaHomi Bhabha National Institute, Mumbai, India.
Jayant S GodaHomi Bhabha National Institute, Mumbai, India.
Homi Bhabha National Institute · INTata Memorial Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: Semantic imaging features have been used for molecular subclassification of high-grade gliomas. Radiomics-based prediction of molecular subgroups has the potential to strategize and individualize therapy. Using MRI texture features, we propose to distinguish between IDH wild type and IDH mutant type high grade gliomas. Methods: Between 2013 and 2020, 100 patients were retrospectively analyzed for the radiomics study. Immunohistochemistry of the pathological specimen was used to initially identify patients for the IDH mutant/wild phenotype and was then confirmed by Sanger's sequencing. Image texture analysis was performed on contrast-enhanced T1 (T1C) and T2 weighted (T2W) MR images. Manual segmentation was performed on MR image slices followed by single-slice multiple sampling image augmentation. Both whole tumor multislice segmentation and single-slice multiple sampling approaches were used to arrive at the best model. Radiomic features were extracted, which included first-order features, second-order (GLCM-Grey level co-occurrence matrix), and shape features. Feature enrichment was done using LASSO (Least Absolute Shrinkage and Selection Operator) regression, followed by radiomic classification using Support Vector Machine (SVM) and a 10-fold cross-validation strategy for model development. The area under the Receiver Operator Characteristic (ROC) curve and predictive accuracy were used as diagnostic metrics to evaluate the model to classify IDH mutant and wild-type subgroups. Results: Multislice analysis resulted in a better model compared to the single-slice multiple-sampling approach. A total of 164 MR-based texture features were extracted, out of which LASSO regression identified 14 distinctive GLCM features for the endpoint, which were used for further model development. The best model was achieved by using combined T1C and T2W MR images using a Quadratic Support Vector Machine Classifier and a 10-fold internal cross-validation approach, which demonstrated a predictive accuracy of 89% with an AUC of 0.89 for each IDH mutant and IDH wild subgroup. Conclusion: A machine learning classifier of radiomic features extracted from multiparametric MRI images (T1C and T2w) provides important diagnostic information for the non-invasive prediction of the IDH mutant or wild-type phenotype of high-grade gliomas and may have potential use in either escalating or de-escalating adjuvant therapy for gliomas or for using targeted agents in the future.

Indexed as

glioblastomamachine learningmolecular subgroupsradiomicstexture feature

Identifiers

PMID36276136
PMCPMC9585657
OpenAlexW4298147004

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.